Telmisartan in high-risk patients intolerant of ACE inhibitors

The Lancet

Volumn 373, Issue 9662, 2009, Pages 458-

  Hall, Alistair ^a   Strauss, Martin H ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; TELMISARTAN; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; HUMANS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC;

EID: 59449108865     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60162-8     Document Type: Letter

References (4)

1. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008) 1174-1183
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
3. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
4. Yusuf S., Diener H.C., Sacco R.L., et al., for the PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008) 1225-1237